SCHEMBL6337465

SCHEMBL6337465

[CH2]C(C)NC(=N)N

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23883124 1.00
SCHEMBL22589402 0.75 NOS3 (0.36)
SCHEMBL1708937 0.75
SCHEMBL2933677 0.75
SCHEMBL2222898 0.75
Hydrochloric Acid SCHEMBL4419382 0.73
Hydrochloric Acid SCHEMBL11107945 0.73 NOS3 (0.35)
SCHEMBL6154815 0.73
SCHEMBL7360709 0.73
Hydrochloric Acid SCHEMBL9034919 0.73

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023194412-A1 SIRNA TARGETING KCNA1 FONDO RICERCA MEDICA S.R.L. (IT) 2023-10-12 WO claimed
EP-3145553-B1 SMALL INTERFERING RNA (SIRNA) FOR THE THERAPY OF TYPE 2 (ADO2) AUTOSOMAL DOMINANT OSTEOPETROSIS CAUSED BY CLCN7 (ADO2 CLCN7-DEPENDENT) GENE MUTATION UNIV DEGLI STUDI DELLAQUILA (IT) 2019-07-31 EP claimed
EP-3145553-A1 SMALL INTERFERING RNA (SIRNA) FOR THE THERAPY OF TYPE 2 (ADO2) AUTOSOMAL DOMINANT OSTEOPETROSIS CAUSED BY CLCN7 (ADO2 CLCN7-DEPENDENT) GENE MUTATION Universita' Degli Studi Dell'Aquila (IT) 2017-03-29 EP claimed
WO-2015177743-A1 SMALL INTERFERING RNA (SIRNA) FOR THE THERAPY OF TYPE 2 (ADO2) AUTOSOMAL DOMINANT OSTEOPETROSIS CAUSED BY CLCN7 (ADO2 CLCN7-DEPENDENT) GENE MUTATION UNIVERSITÀ DEGLI STUDI DELL'AQUILA (IT) 2015-11-26 WO claimed
EP-4398254-A2 COMPOSITIONS AND METHODS FOR ALTERING SECOND MESSENGER SIGNALING Memorial Sloan Kettering Cancer Center (US) 2024-07-10 EP disclosed
US-20240132628-A1 OLIGONUCLEOTIDE ANALOGUE THERAPEUTICS FOR TREATMENT OF NEUROMUSCULAR DISEASE NEUBASE THERAPEUTICS, INC. 2024-04-25 US disclosed
EP-2991655-B1 COMPOSITIONS AND METHODS FOR ALTERING SECOND MESSENGER SIGNALING MEMORIAL SLOAN KETTERING CANCER CENTER (US) 2024-04-10 EP disclosed
EP-4288536-A1 SMALL INTERFERING RNA (SIRNA) FOR THERAPY OF MMIHS CAUSED BY ACTG2 GENE MUTATION Dante Labs S.r.l. (IT) 2023-12-13 EP disclosed
WO-2023233159-A1 THERAPEUTIC COMPOUNDS AND COMPOSITIONS SISAF LTD (GB) 2023-12-07 WO disclosed
WO-2023194412-A1 SIRNA TARGETING KCNA1 FONDO RICERCA MEDICA S.R.L. (IT) 2023-10-12 WO disclosed
US-20230174985-A1 MODIFIED PEPTIDE NUCLEIC ACID COMPOSITIONS NEUBASE THERAPEUTICS, INC. 2023-06-08 US disclosed
US-11603530-B2 Modified peptide nucleic acid compositions NEUBASE THERAPEUTICS, INC. (US) 2023-03-14 US disclosed
CN-102216462-A Branched Cationic Lipids for Nucleic Acid Delivery Systems ENZON PHARMACEUTICALS INC 2011-10-12 CN disclosed
CN-102215820-A Releasable Fusogenic Lipids for Nucleic Acid Delivery Systems ENZON PHARMACEUTICALS INC 2011-10-12 CN disclosed
US-6911554-B2 Isocyano substituted polystyrene carbonate resin for use in 3 and 4 component condensation reactions ARRAY BIOPHARMA INC. (US) 2005-06-28 US disclosed
US-20030225267-A1 Isocyano substituted polystyrene carbonate resin for use in 3 and 4 component condensation reactions ARRAY BIOPHARMA INC. 2003-12-04 US disclosed
US-6114328-A ANTICOAGULANTS; BLOOD DISORDERS DUPONT PHARMACEUTICALS COMPANY (US) 2000-09-05 US disclosed
US-5817751-A IMMOBILIZATION AN AMINOACID ON SUPPORT; CYCLIZATION AFFYMAX TECHNOLOGIES N.V. (GB) 1998-10-06 US disclosed
WO-1996000391-A1 METHODS FOR THE SYNTHESIS OF DIKETOPIPERAZINES AFFYMAX TECHNOLOGIES N.V. (AN) 1996-01-04 WO disclosed
US-4134918-A ENZYME INHIBITORS, ANTIBODY INHIBITORS MERRELL TORAUDE ET COMPAGNIE (FR) 1979-01-16 US disclosed